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Abstract
The herpes simplex virus single-stranded DNA-binding protein, ICP8, localizes initially to structures in the nucleus called prereplicative
sites. As replication proceeds, these sites mature into large globular structures called replication compartments. The details of what signals
or proteins are involved in the redistribution of viral and cellular proteins within the nucleus between prereplicative sites and replication
compartments are poorly understood; however, we showed previously that the dominant-negative d105 ICP8 does not localize to
prereplicative sites and prevents the localization of other viral proteins to prereplicative sites (J. Virol. 74 (2000) 10122). Within the residues
deleted in d105 (1083 to 1168), we identified a region between amino acid residues 1080 and 1135 that was predicted by computer models
to contain two -helices, one with considerable amphipathic nature. We used site-specific and random mutagenesis techniques to identify
residues or structures within this region that are required for proper ICP8 localization within the nucleus. Proline substitutions in the
predicted helix generated ICP8 molecules that did not localize to prereplicative sites and acted as dominant-negative inhibitors. Other
substitutions that altered the charged residues in the predicted -helix to alanine or leucine residues had little or no effect on ICP8
intranuclear localization. The predicted -helix was dispensable for the interaction of ICP8 with the UL9 origin-binding protein. We propose
that this C-terminal -helix is required for localization of ICP8 to prereplicative sites by binding viral or cellular factors that target or retain
ICP8 at specific intranuclear sites.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
The HSV-1 single-stranded DNA-binding protein, ICP8,
is a 128-kDa multifunctional zinc metalloprotein (Gao et al.,
1988; Gupte et al., 1991) encoded by the UL29 gene (Mc-
Geoch et al., 1988). ICP8 preferentially binds single-
stranded DNA over double-stranded DNA in a nonspecific,
cooperative manner (Lee and Knipe, 1985). ICP8 is a nu-
clear protein that, along with the six other HSV replication
proteins, including the viral polymerase (UL30) and its
accessory factor (UL42), the trimeric helicase-primase com-
plex (UL5/UL8/UL52), and the origin-binding protein (UL9),
is required for viral DNA synthesis (Challberg, 1986; Con-
ley et al., 1981). ICP8 can destabilize DNA helices (Boeh-
mer and Lehman, 1993a) and may have a role in viral
genome recombination and processing as shown by its abil-
ity to promote DNA strand transfer (Bortner et al., 1993)
and renaturation of complementary DNA strands (Dutch
and Lehman, 1993). In addition to its role in viral DNA
replication, ICP8 has been shown to regulate viral gene
expression by stimulating late gene expression from prog-
eny genomes (Gao and Knipe, 1991) and repressing tran-
scription from the parental genome (Godowski and Knipe,
1983, 1985, 1986). ICP8 has been shown to interact either
physically or functionally with several viral proteins, in-
cluding associating with the HSV UL9 origin-binding pro-
tein and stimulating its helicase activity (He and Lehman,
2001; Lee and Lehman, 1997; Makhov et al., 1996; Boeh-
mer, 1998; Boehmer and Lehman, 1993b), modulating the
activity of the viral polymerase (UL30) (Chiou et al., 1985;
Hernandez and Lehman, 1990; O’Donnell et al., 1987;
Ruyechan and Weir, 1984), and promoting the helicase
activity of the viral helicase-primase complex (UL5/UL8/
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UL52) (Falkenberg et al., 1998; Hamatake et al., 1997; Le
Gac, et al., 1996). In the absence of viral DNA replication,
e.g., in the presence of the polymerase inhibitor PAA or in
the initial stages of the viral life cycle, ICP8 targets to
structures within the nucleus named prereplicative sites (de
Bruyn Kops and Knipe, 1988; Quinlan et al., 1984). These
nuclear matrix-associated structures form adjacent to cellu-
lar structures referred to as ND10 sites (Ascoli and Maul,
1991; Ishov and Maul, 1996; Lukonis et al., 1997; Maul et
al., 1996; Uprichard and Knipe, 1997). It is believed that at
least some of these prereplicative sites are precursors to
large, globular structures called viral replication compart-
ments, which form as viral DNA replication proceeds (de
Bruyn Kops and Knipe, 1994; Maul et al., 1996; Uprichard
and Knipe, 1997). Various viral processes, such as viral
DNA synthesis (de Bruyn Kops et al., 1998; Phelan et al.,
1997), late gene transcription (Knipe et al., 1987; Phelan et
al., 1997; Randall and Dinwoodie, 1986; Rice et al., 1994),
and capsid assembly (de Bruyn Kops et al., 1998), take
place within replication compartments.
Several functional regions within ICP8 have been
mapped, including a nuclear localization signal located in
the C-terminal 28 amino acid residues (Gao and Knipe,
1992), a DNA-binding region located within amino acid
residues 564–860 (Gao et al., 1988; Gao and Knipe, 1989;
Ruyechan, 1988), two regions involved in cooperative DNA
binding, two cysteine residues, cys245 and cys455 (Dudas
and Ruyechan, 1998), the C-terminal 60 amino acid resi-
dues (Mapelli et al., 2000), and a zinc-binding motif be-
tween amino acid residues 499 and 512 (Gao et al., 1988).
While the regions associated with various activities dis-
cussed above have been mapped, little is known about the
sequence(s) within ICP8 required for intranuclear targeting
to prereplicative sites or replication compartments during
infection. In this study, we describe the construction of
ICP8 point mutants that are deficient for intranuclear tar-
geting. The dominant-negative d105 ICP8 is missing amino
acid residues 1083 to 1168 in the C-terminus of the protein.
When expressed in the context of wild-type viral infection,
either via transfection or in the stably expressing cell line
V2.6, d105 ICP8 reduces viral replication by 50- to 100-fold
(Chen and Knipe, 1996; Gao and Knipe, 1991). The reduced
viral replication is due to a 5-fold reduction in viral DNA
synthesis and a 50- to 100-fold block in late gene transcrip-
tion (Chen and Knipe, 1996). Overexpression of wild-type
ICP8 can overcome this block, suggesting that d105 ICP8
acts in a competitive manner (Gao and Knipe, 1991). While
the d105 ICP8 can still bind single-stranded DNA (Gao and
Knipe, 1991), it does not localize to prereplicative sites or
replication compartments (McNamee et al., 2000); instead,
it is diffusely distributed throughout the nucleus. The mu-
tant d105 protein may exert its dominant-negative activity
in the cell line V2.6 at two stages: (1) preventing the
localization of viral and cellular proteins to prereplicative
sites in 80% of cells, and (2) inhibiting the maturation of
replication compartments from prereplicative sites in the
remaining 20% of cells (McNamee et al., 2000). This sug-
gested that the region deleted in d105 contained sequences
required for intranuclear localization. To further map these
sequences, we introduced mutations into an ICP8-GFP fu-
sion protein gene.
Results
ICP8 localizes initially to prereplicative sites and then to
replication compartments within the nucleus of infected
cells (Quinlan et al., 1984); however, the dominant-negative
d105 ICP8 is distributed diffusely in the nucleus and blocks
the formation of prereplicative sites and replication com-
partments when present during HSV-1 infection (McNamee
et al., 2000). The d105 mutant ICP8 lacks residues 1083–
1168, suggesting that a function required for intranuclear
targeting may lie within this region. To further define what
elements within this region were important for ICP8 in-
tranuclear localization, we used the PHD secondary struc-
ture prediction program (Rost, 1996) to identify regions
with possible -helical or -sheet structures. The region
spanning amino acid residues 1080 to 1135 was predicted to
be -helical with a possible turn at residues 1112 to 1116
(Fig. 1A). No reliable secondary structure prediction was
apparent for the region spanning amino acid residues 1137
to 1196. When the predicted -helix from amino acid res-
idues 1118 to 1135 was plotted on a helical-wheel diagram,
the amphipathic nature was apparent (Fig. 1B). One side of
the predicted helix was composed completely of hydropho-
bic residues, while the other face contained hydrophilic
residues including several negatively charged residues and
one positively charged residue.
Construction and localization of ICP8-GFP point mutants
To determine if this amphipathic -helix was necessary
for localization of ICP8 within the nucleus, we used a
site-directed mutagenesis approach to introduce helix-desta-
bilizing proline residues or charge-to-alanine mutations in
the predicted -helix. We also used a random PCR mu-
tagenesis strategy to generate mutations within the C-termi-
nal 80 amino acid residues of ICP8 to identify other residues
or regions necessary for intranuclear targeting. Mutations
generated by either method were made in a 270-bp SalI
fragment that was sequenced and reinserted into a vector
that expressed the ICP8 coding sequences as a fusion pro-
tein with GFP at its C-terminus. We then evaluated the
ability of the mutant ICP8-GFP fusion proteins to localize
within the nucleus. We transfected Vero cells with plasmids
expressing the mutant ICP8-GFP fusion proteins, and at
24 h after transfection we infected the cells with the HD-2
ICP8 mutant virus in the presence or absence of the viral
DNA synthesis inhibitor phosphonoacetic acid (PAA). We
used the replication-defective HD-2 virus to ensure that the
ICP8 mutant protein could localize within the nucleus in the
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absence of complementing wild-type ICP8. Similar results
were observed when the cells were infected with the wild-
type virus (data not shown). The infected cells were pro-
cessed for GFP fluorescence at 5.5 h postinfection. When
the ICP8-GFP fusion protein was expressed in Vero cells in
the absence of infection, ICP8-GFP was distributed dif-
fusely throughout the nucleus (Fig. 2A). Upon infection, the
ICP8-GFP fusion protein localized to replication compart-
ments (Fig. 2B). If PAA was present during infection, the
ICP8-GFP fusion protein localized to prereplicative sites in
the nucleus (Fig. 2C). The H1126A ICP8-GFP molecule
retained the ability to localize to replication compartments
(Fig. 2D), but the A1128P ICP8-GFP molecule was distrib-
uted diffusely within the nucleus (Fig. 2E). Several single or
double charge-to-alanine substitutions, such as D1119A,
E1123A, H1126A, E1127A, E1129A, D1119A/E1123A, or
H1126A/E1127A, did not significantly alter the ability of
the ICP8-GFP mutant fusion protein to target within the
nucleus (Table 1) with a similar intranuclear localization as
seen for the H1126A ICP8-GFP protein (Fig. 2D) or wild-
type ICP8-GFP (Fig. 2B). Other ICP8 mutants with substi-
tutions outside the predicted -helix, such as L1135H/
F1167L, V1141E, G1149S/H1175R, and P1179Q, also had
little effect on the ability of the ICP8-GFP to localize to
replication compartments (Table 1), but this small number
of mutants by no means saturated this region of ICP8. The
ICP8-GFP molecules with proline substitutions A1121P
ICP8-GFP, L1122P ICP8-GFP, and A1128P ICP8-GFP
(Fig. 2E) exhibited a diffuse nuclear distribution (Table 1),
thus showing an altered ability of the mutant ICP8-GFP
Fig. 1. Secondary structure prediction of a region of ICP8. (A) Secondary
structure prediction for ICP8 amino acid residues 1081 to 1196 by the PHD
program. The ICP8 sequence is found in the “AA” line. The overall
structure prediction is given in the “PHD sec” line with H, -helix; E,
-strand; L, loop. The reliability of the structure prediction is given in the
“Rel sec” line with a range of 0–9 with 9 being the most reliable. (B)
Helical-wheel diagram of amino acid residues 1118 to 1135.
Fig. 2. Intranuclear distributions of ICP8-GFP proteins. Vero cells were transfected with plasmids expressing the indicated ICP8-GFP molecule. At 24 h
posttransfection, the cells were infected with the HD-2 virus. At 5.5 h postinfection, the cells were prepared to visualize GFP. (A) ICP8-GFP distribution
before infection with HD-2 virus. (B) ICP8-GFP distribution after infection with HD-2 virus. (C) ICP8-GFP distribution after infection with HD-2 virus in
the presence of PAA. (D) Mutant H1126A-GFP distribution after HD-2 virus infection. (E) Mutant A1128P-GFP distribution after HD-2 virus infection. The
nuclear portions of representative cells are shown.
Table 1
Intranuclear distribution of mutant ICP8-GFP fusion proteinsa
ICP8 gene transfected Intranuclear distribution
Wild type Compartments
Wild type  PAA Prereplicative sites
D1119A Compartments
E1123A Compartments
H1126A Compartments
E1129A Compartments
D1119A/E1123A Compartments
H1126A/E1127A Compartments
L1122P Diffuse
A1128P Diffuse
A1121P Diffuse
S1133G Compartments
L1135H/F1167L Compartments
V1141E Compartments
F1144C Diffuse
G1149S/H1175R Compartments
P1179Q Compartments
C1149R/N1153S/
K1171N
Diffuse
a Vero cells transfected with plasmids expressing the indicated ICP8
molecules were infected with HD-2 virus at 24 h posttransfection. Cells
were fixed at 5.5 to 7 h postinfection.
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proteins to localize properly in the nucleus, presumably by
disrupting the predicted -helix in this region. However, we
cannot rule out the possibility that the alanine or the leucine
residues themselves were required for proper structure and
function. The S1133G substitution would be predicted to
disrupt an -helix; however, this substitution was at the very
end of the predicted -helix and may not have a dramatic
effect upon the structural integrity of the helix. The F1144C
substitution was interesting in that it altered the total num-
ber of cysteines in ICP8. It was possible that the introduc-
tion of another cysteine in the C-terminus of ICP8 disrupted
structure within this region or more generally within ICP8.
Construction and localization of ICP8 point mutants
Once ICP8-GFP mutants that were defective for intranu-
clear localization were identified, we constructed vectors
expressing the mutant proteins without GFP fused to the
C-terminus to ensure that the GFP moiety itself was not
contributing to the observed localization defect. Fig. 3
shows a Western blot of lysates from transfected Vero cells
expressing the ICP8 mutants. The mutant proteins appeared
to migrate slower than the wild-type protein due to an extra
18 amino acid residues at the C-terminus that remained after
removing the GFP coding sequences. These extra residues
did not significantly alter the function of the ICP8 proteins
because certain mutants, such as the single or double
charge-to-alanine substitutions, could still localize to repli-
cation compartments (Fig. 4) or complement an ICP8 null
virus (Table 2).
We first determined if the mutant ICP8 molecules could
localize properly within the nucleus in HD-2 infected Vero
cells. In this experiment, we transfected Vero cells with
equal amounts of the plasmid encoding the indicated mutant
ICP8. At 24 h posttransfection, we infected the Vero cells
with the HD-2 virus. At 5.5 h postinfection, the cells were
processed for immunofluorescence to detect ICP8 using the
39S monoclonal antibody. The 39S antibody generally only
recognizes wild-type ICP8 at prereplicative sites or in rep-
lication compartments (S.L. Uprichard and D.M. Knipe,
manuscript submitted for publication). We have evidence
Fig. 3. Expression of ICP8 proteins. Vero cells transfected with plasmids
expressing the indicated ICP8 molecule were harvested at 48 h posttrans-
fection. An equal volume of each lysate was separated by SDS-PAGE,
transferred to a membrane, and probed with the 3–83 polyclonal antibody.
Fig. 4. Localization of ICP8 proteins in infected cells. Vero cells were infected with HD-2 virus at 48 h posttransfection. At 5 h postinfection, the cells were
processed for immunofluorescence. (A) wt ICP8, (B) L1135H/F1167L ICP8, (C) S1133G ICP8, (D) L1122P ICP8, (E) A1121P ICP8, (F) V1141E ICP8, (G)
G1149S/H1175R ICP8, (H) F1144C ICP8, (I) A1128P ICP8, (J) D1119A/E1123A ICP8, (K) H1126A/E1127A ICP8, and (L) C1149R/N1153S/K1171N
ICP8. The 39S monoclonal antibody was used to detect ICP8 molecules in all panels except for (L), which required the 3–83 polyclonal antibody.
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that ICP8 undergoes a conformational change induced by
interaction with other viral proteins or DNA within the
nucleus to form or unmask the 39S epitope (S.L. Uprichard
and D.M. Knipe, manuscript submitted for publication).
Wild-type ICP8 localized to replication compartments (Fig.
4A), but the L1122P (Fig. 4D), A1121P (Fig. 4E), A1128P
(Fig. 4I), and F1144C (Fig. 4H) ICP8 molecules showed
primarily a diffuse distribution in the nucleus of the major-
ity of the cells observed (see Figs. 4D and H for examples),
but small structures were occasionally observed in a few
cells (see Figs. 4E and I for examples) that we presume to
be nonspecific aggregates of mutant protein. The proline
mutant ICP8 molecules were distributed diffusely in the
nucleus (Figs. 4D, E, and I), suggesting that the -helix in
the C-terminus of ICP8 is important for intranuclear local-
ization. The small number of prereplicative sites observed
may reflect the ability of ICP8 interacting proteins to par-
tially complement the mutant’s structural instability by
binding and stabilizing local structure. The recognition of
the mutant ICP8 molecules by 39S monoclonal antibody
also suggested that the global protein structure of the d105,
A1121P, A1128P, and F1144C ICP8 molecules was intact
because they could form the 39S epitope. The triple mutant
C1149R/N1153S/K1171N was not recognized by the 39S
monoclonal antibody. When expressed without GFP fused
to its C-terminus, the triple mutant did not localize to the
nucleus; rather, the majority of it was observed in the
cytoplasm when detected by immunofluorescence using the
3-83 polyclonal anti-ICP8 antibody (Fig. 4L). The K1171N
substitution in this mutant altered a lysine residue in the
predicted nuclear localization signal (NLS) to an uncharged
asparagine, thus possibly disrupting the NLS and subse-
quently altering the ability to localize to the nucleus. The
GFP fusion version of this mutant localized to the nucleus,
suggesting that the presence of GFP at the C-terminus of
this mutant somehow suppressed the nuclear localization
defect. This result confirmed that nuclear targeting is re-
quired for acquisition of the epitope recognized by the 39S
monoclonal antibody.
HD-2 complementation assay
To determine if the ICP8 point mutants could comple-
ment the growth of an ICP8-deficient virus, we infected
Vero cells expressing the indicated mutants with the HD-2
ICP8 mutant virus. Only the double mutant D1119A/
E1123A ICP8, which retained the ability to properly target
within the nucleus, could complement the growth of the
HD-2 virus to near wild-type levels observed with the trans-
fection of the wild-type control plasmid pCMV-8.3 plasmid
(Table 2). The F1144C, A1121P, and A1128P ICP8 mole-
cules all failed to complement HD-2, with the viral yield
near the levels of those obtained when the control plasmid
pCI or a plasmid expressing d105 ICP8 were used (Table 2).
Thus the ICP8 mutants that did not localize to replication
compartments, such as the F1144C, A1121P, and A1128P
ICP8 molecules, failed to complement the growth of an
ICP8 deficient virus.
Construction and localization of a C-terminal region of
ICP8 fused to GFP
The results described above suggested that the C-termi-
nal portion of ICP8 containing the -helix may comprise a
targeting or retention signal required for localization to viral
replication structures. If this were true, the C-terminal por-
tion of ICP8 might be sufficient to target a heterologous
protein to prereplicative sites or replication compartments
during infection. We tested this by fusing amino acid resi-
dues 1007–1196 of ICP8 to the N-terminus of GFP, which
generated a fusion protein that we named cterm8-GFP. In
transfected Vero cells, the cterm8-GFP protein migrated
with approximately the predicted mass of 48 kDa (data not
shown). We ascertained if this region of ICP8 was sufficient
for intranuclear localization to replication compartments by
determining if it could efficiently localize to specific struc-
tures within the nucleus in the context of HSV infection.
The cterm8-GFP fusion protein retained the ICP8 NLS (Gao
and Knipe, 1992), so it could still target into the nucleus.
Vero cells transfected with plasmids that expressed either
wild-type ICP8-GFP or cterm8-GFP were subsequently
mock-infected (Figs. 5A and C, respectively) or infected
with HSV (Figs. 5B and D, respectively). At 6 h postinfec-
tion with wild-type virus, ICP8-GFP was clearly localized
to viral replication compartments (Fig. 5B). In contrast, the
cterm8-GFP fusion protein was distributed diffusely in the
nucleus after infection with HSV (Fig. 5D), suggesting that
the cterm8-GFP protein localized poorly, if at all, to repli-
cation compartments. Thus, the C-terminal 190 amino acid
residues of ICP8 were not sufficient to specifically target to
or retain GFP at replication compartments.
Table 2
Complementation of HD-2 ICP8 mutant virus by wt and mutant ICP8
moleculesa
Plasmid transfected % wild-type titerb
Experiment 1
pCI vector plasmid 0.67
pCMV-ICP8 (wt) 100
pCMV-d105 0.43
pCMV-D1119A/E1123A 57
pCMV-A1121P 0.23
pCMV-F1144C 0.76
Experiment 2
pCI vector plasmid 0.47
pCMV-ICP8 100
pCMV-d105 0.47
pCMV-D1119A/E1123A 102
pCMV-A1128P 0.50
a Vero cells expressing the indicated ICP8 molecule were infected with
HD-2 at 24 h posttransfection.
b Yield was determined by titration on an ICP8-complementing cell line.
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The dominant-negative d105 ICP8 mutant binds UL9
It was also possible that this portion of ICP8 interacted
with other viral or cellular proteins that were required for
intranuclear localization. It is known that ICP8 interacts
with the C-terminus of the HSV UL9 origin-binding protein
(Boehmer and Lehman, 1993b). Thus, it was conceivable
that the predicted -helix in ICP8 was required for inter-
acting with UL9. We tested this by determining the ability of
wild-type or d105 ICP8 to bind a Staphylococcus aureus
protein A-UL9 fusion protein immobilized on IgG Sepha-
rose (Arbuckle and Stow, 1993). Both the wild-type and the
d105 ICP8 proteins bound the wild-type B1 protein A-UL9
fusion protein (Fig. 6). The mutant D27 protein A-UL9
fusion protein, which was previously shown not to bind
ICP8 (Boehmer et al., 1994), bound neither the wild-type
nor the d105 ICP8 proteins (Fig. 6). Thus, residues 1083 to
1168 of ICP8, including the predicted -helix, were not
required for interactions with the UL9 origin-binding pro-
tein.
Altered UL42 localization in the presence
of the ICP8-GFP point mutants
In addition to not localizing to prereplicative sites itself,
the dominant-negative d105 ICP8 protein inhibits the local-
ization of other viral proteins to prereplicative sites (Mc-
Namee et al., 2000). We tested the ability of the ICP8-GFP
mutants to block the intranuclear localization of another
viral protein to determine if the point mutants acted in a
dominant-negative manner similar to d105 ICP8. We trans-
fected plasmids encoding ICP8-GFP mutant proteins into
Vero cells and at 24 h postinfection infected with wild-type
KOS 1.1 virus. We then used indirect immunofluorescence
at 5.5 h postinfection to visualize the intranuclear distribu-
tion of the UL42 polymerase processivity factor in cells that
expressed the mutant ICP8-GFP protein. The wild-type
ICP8-GFP fusion protein and the double mutant H1126A/
E1127A ICP8-GFP did not alter the localization of UL42 to
replication compartments (Figs. 7A and B, respectively),
whereas in the cells expressing the L1122P ICP8-GFP,
A1128P ICP8-GFP, and A1121P ICP8-GFP, UL42 was dis-
Fig. 5. Distribution of the cterm8-GFP fusion protein. Vero cells were
transfected with plasmid that expressed either wild-type ICP8-GFP (A and
B) or the cterm8-GFP (C and D) fusion proteins. Cells were either mock-
infected or infected with KOS1.1 at 24 h posttransfection. At 6 h postin-
fection, the cells were harvested for analysis. (A) distribution of ICP8-GFP
in a mock-infected cell, (B) distribution of ICP8-GFP in an HSV infected
cell, (C) distribution of cterm8-GFP in a mock-infected cell, and (D)
distribution of cterm8-GFP in an HSV-infected cell.
Fig. 6. Interaction of wild-type and d105 ICP8 with UL9. Wild-type or
d105 extracts from transfected 293 cells were incubated with either the
wild-type B1 protein A-UL9 fusion protein or the mutant D27 fusion
protein. After the unbound (FT) fraction was collected, the IgG Sepharose
was washed with 100 mM salt buffer (LS) and subsequently 1 M salt buffer
(HS). A portion (1/10 vol) of each fraction was separated by SDS-PAGE,
transferred to a membrane, and probed with 3–83 polyclonal antibody.
Fig. 7. Effect of mutant ICP8 proteins on the localization of UL42. Vero
cells transfected with the indicated ICP8-GFP expression plasmid were
infected 24 h later with KOS 1.1 virus. Cells were processed for immu-
nofluorescence at 5.5 h postinfection. UL42 was detected by the 5H11D6
monoclonal antibody (A, C, E, G, I, and K). ICP8-GFP proteins were
detected by GFP fluorescence (B, D, F, H, J, and L). (A) UL42 with wt
ICP8-GFP; (B) ICP8-GFP; (C) UL42 with L1122P-GFP; (D) L1122P-GFP;
(E) UL42 with F1144C-GFP; (F) F1144C-GFP; (G) UL42 with A1128P-
GFP; (H) A1128P-GFP; (I) UL42 with A1121P-GFP; (J) A1121P-GFP;
(K) UL42 with H1126A/E1127A-GFP; and (L) H1126A/E1127A-GFP.
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tributed diffusely within the nucleus (Figs. 7C, G, and I,
respectively). Small structures containing F1144C ICP8-
GFP and UL42 were observed in some cells (Figs. 7E and
F), but the structures were not as large as those observed in
wild-type ICP8-GFP expressing cells, indicating that this
mutant may have a weak inhibitory activity. The presence of
ICP8 from the wild-type genome may partially complement
the localization defect observed with F1144C ICP8-GFP
(Fig. 7F). Small structures within the nucleus containing
A1121P ICP8-GFP (Fig. 7J) were observed, but these struc-
tures did not colocalize with UL42, so these structures may
be aggregates of the mutant protein within the nucleus or
may also be due to the presence of wild-type ICP8 ex-
pressed as a result of wild-type infection. We conclude that
the three proline substitutions that disrupted the predicted
-helix all blocked the proper intranuclear localization of
UL42. This block may manifest itself at multiple stages
during viral infection. The proline substitution mutants may
block the initiation of viral replication, thus preventing
replication compartment formation, or the proline mutants
may bind a factor required specifically for the targeting of
viral proteins to replication compartments, thus preventing
the accumulation at specific intranuclear sites.
The ICP8 proline point mutants act in a dominant-
negative manner
To determine if the mutants that blocked UL42 intranu-
clear localization also blocked viral replication in a domi-
nant-negative manner, we performed plaque-reduction as-
says. Wild-type viral DNA was cotransfected with plasmids
expressing wild-type ICP8 (pCMV-8.3), a mutant ICP8
(pCMV-d105, pCMV-F1144C, pCMV-A1121P, pCMV-
L1122P, or pCMV-A1128P), or the vector plasmid (pCI). If
the expressed protein acted in a dominant-negative manner,
the number of plaques would be reduced. The expression of
wild-type or F1144C ICP8 did not significantly reduce the
number of plaques compared to the vector pCI plasmid
control (Table 3). In contrast, A1121P ICP8, L1122P ICP8,
and A1128P ICP8 reduced the plaque number to the levels
observed in the presence of the dominant-negative d105
ICP8 (Table 3). These results suggested that A1121P ICP8,
L1122P ICP8, and A1128P ICP8 acted in an dominant-
negative manner similar to d105 ICP8, possibly by compet-
itively binding and titrating out limited viral or cellular
factors required for viral replication that would normally
interact with wild-type ICP8.
Discussion
ICP8 localizes initially within the nucleus to nuclear-
matrix-associated prereplicative sites (Quinlan et al., 1984),
which form adjacent to cellular ND10 sites (Ishov and
Maul, 1996; Lukonis et al., 1997; Maul et al., 1996; Up-
richard and Knipe, 1997). Following the onset of viral DNA
replication, ICP8 localizes to replication compartments (de
Bruyn Kops and Knipe, 1988; Quinlan et al., 1984), which
grow and coalesce to form larger replication compartment
structures that eventually fill the nucleus (Taylor et al.,
2003). The mechanisms required for intranuclear localiza-
tion and compartmentalization are poorly understood. To
further the studies of intranuclear targeting and compart-
mentalization, we used the HSV-1 single-stranded DNA-
binding protein, ICP8, as a model protein.
Requirements for ICP8 intranuclear localization
To identify residues within ICP8 required for intranu-
clear localization, we mutagenized a specific region of ICP8
in an ICP8-GFP fusion protein. In this report, we demon-
strated the effect of introducing point mutations into a
region in the C-terminus of ICP8 predicted to be an amphi-
pathic -helix. We isolated three types of mutations, which
will be discussed in more detail below, consisting of (1)
substitutions that did not alter the ability of ICP8 to localize
within the nucleus, (2) a substitution, F1144C, that altered
the ability of ICP8 to localize within the nucleus, but did not
have a strong dominant-negative phenotype, and (3) substi-
tutions that abolished the ability of ICP8 to localize within
the nucleus and had a strong-dominant negative phenotype
as shown by the ability to inhibit viral growth in a plaque
reduction assay. ICP8 mutant molecules which had one or
two charged residues substituted with alanines, such as
D1119A, E1123A, H1126A, E1127A, E1129A, D1119A/
E1123A, and I11126A/E1127A, retained the ability to lo-
calize to structures within the nucleus. This suggests that
individual charged residues within this region of ICP8 are
not critical for intranuclear localization. Other substitutions
outside the region predicted to contain an -helix had little
or no effect on the intranuclear localization of ICP8. These
substitutions, such as L1135H/F1167L, V1141E, and
P1179Q, were in a region that contained no definitive sec-
ondary structure as predicted by the PHD program. The
exception to this was F1144C ICP8, which had an altered
number of cysteine residues in the protein. Wild-type ICP8
contains 22 cysteines, and it has previously been shown that
Table 3
Inhibition of HSV-1 plaque formation by mutant ICP8 moleculesa
Plasmid transfected Plaque numberb % WT
pCI vector plasmid 286 139
pCMV-ICP8 205 100
pCMV-d105 6 3
pCMV-F1144C 88 43
pCMV-A1121P 11 5
pCMV-L1122P 7 3
pCMV-A1128P 5 2
a Infectious wild-type viral DNA (0.25 g) was cotransfected with 0.5
g of plasmid expressing the indicated ICP8 molecule.
b Plaques were counted at 5 days after transfection.
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ICP8 has two electrophoretic conformational forms (Knipe
et al., 1982). It was suggested that these two forms of ICP8
coexist within an infected cell based on the evidence that (1)
the relative abundance of one form or the other depended
upon the time of harvest postinfection, (2) that the prepa-
ration of extracts was performed in the presence of reducing
agents that would prevent spontaneous disulfide bond for-
mation during the process, and (3) that the two forms were
still observed when the extracts were reacted with the alky-
lating agent N-ethylmaleimide (NEM) (Knipe et al., 1982).
It is possible that the introduction of an additional cysteine
in F1144C ICP8 may have deleterious effects on ICP8
function or structure by disrupting proper cysteine pairing.
It has also been shown that cysteines may be involved in
optimal ICP8 DNA binding as treatment of ICP8 with NEM
inhibited DNA binding (Ruyechan, 1988). In addition, the
C-terminus of ICP8 has been shown to be required for
cooperative DNA binding (Mapelli et al., 2000); thus, the
introduction of another cysteine (or the removal of the
phenylalanine residue) may interfere with optimal cooper-
ative DNA binding. The introduction of the F1144C substi-
tution did not result in a strong dominant-negative pheno-
type, suggesting that this mutant cannot act as a competitive
inhibitor of wild-type ICP8 function. In contrast, substitu-
tions that would disrupt the predicted -helix with a proline,
such as L1122P, A1128P, and A1121P, lost the ability to
localize to prereplicative sites and replication compart-
ments. We believe that the disruptions alter the structural
integrity of an -helix that is required to interact with other
viral or cellular proteins that are needed for proper intranu-
clear targeting.
ICP8 interactions with infected cell components
When ICP8 is expressed in the absence of the other viral
replication proteins, it is distributed diffusely within the
nucleus and it is poorly recognized by the 39S conforma-
tion-specific, monoclonal anti-ICP8 antibody, which gener-
ally only recognizes ICP8 at prereplicative sites or in rep-
lication compartments (S.L. Uprichard and D.M. Knipe,
manuscript submitted for publication). We hypothesize that
ICP8 interacts with other viral or cellular factors, which
induces a conformational change in ICP8, and that it is this
conformational change that forms or exposes the epitope
that reacts with the 39S monoclonal antibody. ICP8 is
known to directly bind DNA (Lee and Knipe, 1985) and the
origin-binding protein (Boehmer et al., 1994; Boehmer and
Lehman, 1993b), suggesting that one or both of these mol-
ecules may be involved. It is also known that the presence
of the helicase-primase complex is sufficient to localize
ICP8 to punctate prereplicative sites in transfected cells
(Liptak et al., 1996), so interaction(s) with one or more of
components of the heterotrimeric helicase-primase complex
may be required to drive a conformational change. Upon
binding the other viral replication proteins, ICP8 can then
interact with other viral or cellular factors required for
targeting or anchoring ICP8 and its associated proteins to
prereplicative sites. The exact identity of the viral or cellular
factors involved remains unknown, but they may include
viral DNA, other viral or cellular proteins, and components
of the nuclear matrix. It may be possible to identify proteins
that induce the ICP8 conformational change by generating
mutations in d105 that relieve its dominant-negative phe-
notype. For example, if either UL9 or DNA binding are
required to drive the conformational change to generate a
dominant-negative protein, than the disruption of these ac-
tivities or interactions may produce a version of d105 that
no longer has dominant-negative activity.
We propose that a region in the C-terminus of ICP8 that
is predicted to contain an amphipathic -helix spanning
amino acid residues 1083 to 1135 is critical for intranuclear
targeting or retention, possibly by interacting with viral or
cellular factors that target or retain ICP8 and its associated
proteins within the nucleus to prereplicative sites. Other
regions of the ICP8 protein are likely to be required for
intranuclear localization because the C-terminal 190 amino
acid residues were not sufficient to relocalize GFP from a
diffuse distribution within the nucleus to replication com-
partments. It is possible that the proline mutants and d105
ICP8 act in an inhibitory manner by binding one or more
viral or cellular factors required for proper intranuclear
localization, but cannot interact with others. Thus, these
mutant ICP8 proteins may act to titrate out viral or cellular
factors required for localization to prereplicative sites in the
nucleus. The ICP8 proline substitutions still reacted with the
39S conformation-specific antibody, suggesting that the
mutants were still capable of interacting with the proteins
required to form or unmask the 39S epitope. We have also
shown that the UL9 origin-binding protein and the d105
ICP8 bind, so this interaction is not significantly altered by
the deletion in this region. It would be informative to iden-
tify other viral or cellular factors that bind ICP8 to better
define the interaction. Once identified, the role of these
interactions in the targeting of proteins within the nucleus
may be elucidated.
General mechanisms for intranuclear
compartmentalization
The nucleus does not contain obvious physical barriers,
such as the lipid membrane that separates the cytoplasm
from the interior of the endoplasmic reticulum or the nu-
clear membrane with its nuclear pores that act as gates to
separate the contents of the cytoplasm and the nucleus, that
would facilitate nuclear compartmentalization. However,
some mechanism(s) must exist to ensure proper intranuclear
targeting and compartmentalization. Some attempts have
been made to identify regions or signals in nuclear proteins
or RNA that may constitute targeting/sorting/retention sig-
nals that direct or hold proteins or RNA within specific
regions of the nucleus, such as the nucleolus (Lohrum et al.,
2000) or the nuclear speckles (Eilbracht and Schmidt-Lach-
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mann; 2001). While some progress is being made in deter-
mining the minimal requirements for targeting to the above-
noted nuclear subcompartments, it is still unclear what
mechanism is involved in targeting or anchoring proteins to
the nuclear-matrix-associated ND10 sites. It is known that a
small, ubiquitin-like molecule, called SUMO or PIC1, can
be covalently attached to the ND10-associated protein
PML, and that this modification is required for PML to
associate with ND10 (Boddy et al., 1996; Muller et al.,
1998; Sternsdorf et al., 1997). Another ND10-associated
protein, Sp100, is also “SUMOylated,” but this is not re-
quired for ND10 association, suggesting that SUMO mod-
ification itself is not intrinsically an intranuclear targeting
mechanism (Sternsdorf et al., 1997). However, Sp100 and
other ND10-associated proteins do require PML-SUMO for
their association with ND10, suggesting that PML-SUMO
may play a critical role in recruiting other cellular proteins
to the site (Zhong et al., 2000). To date, there is no evidence
that ICP8 is modified by the addition of SUMO or that it
interacts specifically with PML-SUMO.
There is little sequence or structural similarity between
viral proteins that associate with ND10, such as the HSV
ICP0 protein (Everett and Maul, 1994), the cytomegalovirus
ie1 and ie2 proteins (Ahn et al., 1998; Ishov et al., 1997), the
Epstein-Barr virus EBNA-5 protein (Szekely et al., 1996),
the SV40 large T antigen (Carvalho et al., 1995; Ishov and
Maul, 1996), and the adenovirus E1A and E4orf3 proteins
(Carvalho et al., 1995), making it difficult to determine the
minimum requirements for intranuclear localization or as-
sociation with ND10. At least one study has reported that
the adenovirus E1A protein requires the (D)LXCXE motif
for its association with ND10 structures (Carvalho et al.,
1995). Although this motif is also implicated in pRb bind-
ing, it was found that other E1A mutants incapable of
binding pRb, but retain the (D)LXCXE motif, still associate
with ND10 in transfected cells, suggesting that pRb binding
is not required for targeting or retention (Carvalho et al.,
1995). ICP8 contains the sequence LXLXE between amino
acid residues 1089 and 1093, which is disrupted in d105
ICP8. It is possible that this sequence may be similar to the
LXCXE motif and may work via a related mechanism. The
exact requirements for the HSV-1 ICP0 intranuclear target-
ing are also poorly understood. Although the RING finger
motif in the N-terminus of ICP0 is required for the disrup-
tion of ND10 (Everett and Maul, 1994), it is not required for
association with ND10; however, a region in the C-terminus
required for ND10 association has been identified (Everett
and Maul, 1994; Maul and Everett, 1994). These differences
described above as well as the lack of significant sequence
similarities may suggest that multiple pathways or mecha-
nisms are involved in the targeting or retention of viral
proteins to specific sites within the nucleus. Efforts to crys-
tallize ICP8 (Mapelli and Tucker, 1999) to determine its
three-dimensional structure may be critical for the further
understanding of how ICP8 may bind and target cellular or
viral proteins to prereplicative sites and replication com-
partments. In the future, it may be possible to take advan-
tage of these interactions as pharmacological targets to
prevent intranuclear targeting of proteins to prereplicative
sites and thus limit viral replication.
Materials and methods
Cells and viruses
African green monkey kidney (Vero) and human 293
cells were grown and maintained in Dulbecco’s modified
Eagle’s medium (Mediatech, Inc.) with 5% fetal bovine
serum (Gibco)  5% bovine calf serum (Hyclone), glu-
tamine, streptomycin, and penicillin (DMEM  10% FCS).
The ICP8-expressing cell lines S2 (Gao and Knipe, 1989)
and V827 (Da Costa et al., 2000) were grown and main-
tained in DMEM  10% FCS plus G418 (400 g/ml).
The herpes simplex virus 1 KOS1.1 wild-type strain,
originally obtained from M. Levine, was propagated and
assayed on Vero cells. The HD-2 ICP8 mutant virus (Gao
and Knipe, 1989) was propagated on either S2 or V827
cells, which contain the ICP8 gene or the ICP8 and ICP27
genes, respectively. All infections were conducted at an
m.o.i. of 20.
Plasmids
The plasmids pCMV-8.3, pCMV-d105, and pCMV-
ICP8GFP express wild-type ICP8, the mutant d105 ICP8,
and ICP8-GFP, respectively, under the control of the CMV
immediate early promoter. The plasmid pSVd101 expresses
the d101 mutant ICP8, which lacks residues 17 to 563 (Gao
and Knipe, 1989). The plasmids pCMV-8.3 and pCMV-
d105 were generated by removing a 3.8-kbp EcoRI/AvrII
fragment containing the entire ICP8 ORF from pSV8.3
(Gao and Knipe, 1991) or pSVd105 (Gao and Knipe, 1991)
and cloning them into the EcoRI and XbaI sites of pCI,
respectively. To construct pCMV-ICP8GFP, a 732-bp NotI
fragment containing an enhanced green fluorescent protein
(GFP) open-reading frame from pGreenLantern (Gibco-
BRL) was cloned into the NotI site of pCIAflII to generate
pCIA-GFP. A 3.8-kbp EcoRI/AvrII fragment containing
the entire ICP8 ORF from pSV8.3 was cloned into the
EcoRI and XbaI sites of pCIA-GFP. The fusion protein
ORF was generated by mutating the ICP8 stop codon via
PCR-mediated site-directed mutagenesis with Pfu DNA
polymerase (Stratagene) (one cycle 95°C 2 min; 12 cycles
95°C 30 s, 55°C 1 min, 68°C 18 min). The two primers used
for changing the stop codon to an arginine residue were
5-CAACCCCTCTCAGCATATCCAACG-3 (antisense)
and 5-CGTTGGATATGCTGAGAGGGGTTG-3 (sense)
(Life Technologies). The altered nucleotide is underlined.
After PCR amplification, the reaction was digested with
DpnI, and 1 l of the reaction was used to transform
bacteria. Candidate clones were sequenced to ensure that the
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appropriate sequence change was introduced. The site-di-
rected point mutants were constructed by mutagenizing a
270 bp SalI fragment (containing ICP8 sequence coding for
amino acids 1117 to 1196) removed from pCMV-ICP8GFP
and cloned into the plasmid vector pCIAflII. Altering the
270-bp sequence in the pCI background allowed us to fully
sequence the clones and to minimize the introduction sec-
ondary mutations that might have arisen during the mu-
tagenesis protocol. Once sequenced, the SalI fragment was
recloned into the SalI site of either pCMV-8.3 or pCMV-
ICP8GFP to express the indicated mutant ICP8 or ICP8-
GFP proteins. The GeneEditor in vitro site-directed mu-
tagenesis system (Promega) was used to construct the site-
directed point mutants. The primers used to construct the
site-directed point mutants were L1122P, 5-ACGCGGC-
CCCGGAGGTGGCGCAC; E1127A, 5-AGGTGGCG-
CACGCGGCCGAGGCC; E1129A, 5-ACGAGGCCGCG-
GCCCTAGTCAGC; A1128P, 5-TGGCGCACGCCGAG-
GCCCTAG; H1126A/E1127A, 5-GACTAGGGCCTCG-
GCCGCGGCCGCCACCTCCAGGGCCGCGTC; E1119A,
5-GACGCGGCCCTGGCGGTGGCGCACGAGGCCGA-
GGCC, D1119A/E1123A, 5-GGCGAGTGGTCGACGG-
CCGCGGCCCTGGCGGTGGCGGCCGCGGCC. The sin-
gle mutant E1123A was isolated as a clone resulting from a
mutagenesis reaction that was intended to generate the dou-
ble mutant D1119A/E1123A, but only the E1123A muta-
tion was generated in that particular clone.
The random point mutations were introduced using an
error-prone PCR protocol. The PCR (7 mM MgCl2, 0.5 mM
MnCl2, 1 mM dCTP and dTTP, 0.2 mM dGTP and dATP,
0.3 M primers, 50 ng pCMV-cterm8-GFP template DNA
in a total volume of 50 l) was run for 30 cycles (1 min at 94
C, 1 min at 45 C, 1 min at 72 C). The forward primer was
5-CCTTATTTTTGACCGCACCCG and the reverse primer
was 5-CGCCGATGGAGTGTTCTGTTG. The 270-bp SalI
fragment was isolated from the 1000-bp fragment generated by
the PCR and cloned into the SalI site of pCMV-ICP8GFP to
screen for mutations that altered ICP8-GFP localization. With
this system, only mutants that retained the ICP8 reading frame
would give rise to an ICP8-GFP fusion protein that could be
detected by GFP fluorescence. We picked 64 colonies for
analysis. Of those, 22 expressed an ICP8-GFP protein that was
detectable by GFP fluorescence in transfected Vero cells. We
sequenced the 22 isolates to determine if there were mutations
in the ICP8 sequence. Of these 22 clones, 10 clones had one or
more mutations that resulted in an altered amino acid se-
quence.
The pCMV-cterm8GFP plasmid was constructed by first
generating a second NheI site in the plasmid pCMV-
ICP8GFP using the GeneEditor site-direct mutagenesis kit
(Promega). The primer used to generate the NheI site was
5-GAACTGGGCTAGCCTGATGG. The resulting plas-
mid was digested with NheI to remove a 3.5-kb fragment.
The vector was religated to generate the plasmid pCMV-
cterm8GFP. This plasmid expresses ICP8 amino acid resi-
dues 1007 to 1196 fused to the N-terminus of GFP. The
nuclear localization signal was left intact in the ICP8 se-
quence.
Plasmids pB1 and pD27 expressing amino acid residues
535 to 851 or 535 to 824 of the origin-binding protein UL9
fused to the C-terminus of Staphylococcus aureus protein A
(Arbuckle and Stow, 1993; Boehmer and Lehman, 1993b),
respectively, were kindly provided by Nigel Stow (MRC
Virology Unit, Institute of Virology, Glasgow).
Indirect immunofluorescence and GFP fluorescence
For indirect immunofluorescence and GFP fluorescence
studies, Vero cells were plated on 12-mm coverslips in a
24-well plate. At the indicated times posttransfection or
postinfection, the cells were washed briefly in PBS and then
fixed for 5 min in 3.7% formaldehyde in PBS. After wash-
ing with PBS for 5 min, the cells were subsequently per-
meabilized with 20°C acetone for 2 min. The cells were
then rinsed in distilled water and washed for 5 min in PBS.
Primary antibody was then applied at a 1:50 dilution of one
of the following for the 39S anti-ICP8 monoclonal antibody
(Showalter et al., 1981) and the 5H11D6 anti-UL42 mono-
clonal antibody (Gao et al., 1993), or 1:200 dilution for the
3-83 anti-ICP8 polyclonal antibody (Knipe et al., 1987).
After washing three times for 5 min in PBS, a 1:100 dilution
of a rhodamine-conjugated goat anti-mouse antibody was
used as a secondary antibody for detection. After a final
wash in PBS, the coverslips were mounted onto glass slides
with gelatin. Cells were viewed with an Axioplan 2 (Zeiss)
microscope equipped with an Orea cooled CCD camera
(Hamamatsu Photonics). A Zeiss 63X plan Apochromat
objective was used. Images were collected with the Open-
Lab software package (Improvision). Figures were prepared
with Canvas 5.0 (Deneba).
Complementation of ICP8 mutant virus
Vero cells were transfected with the indicated plasmids
expressing either wild-type or mutant ICP8 using Lipo-
fectamine reagent (Gibco-BRL) following the manufactur-
er’s recommendations. At 24 h posttransfection, the cells
were infected with the HD-2 ICP8 mutant virus. The cells
were washed twice (40 mM sodium citrate, 135 mM NaCl,
10 mM KCl, pH 3.0) for 30 s before being overlayed with
new media. One day later, the cells were harvested by two
rounds of freeze/thaw and sonication. The viral yield was
determined by titration on the V827 complementing cell
line.
Preparation of protein extracts
Protein extracts were obtained from two 150-cm2 culture
flasks of 293 cells transfected with pCMV8.3 and pCMV-
d105. At 48 h posttransfection, the cells were washed twice
with phosphate-buffered saline, collected by centrifugation,
and resuspended in 2 ml of high salt buffer (1.2 M NaCl, 20
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mM HEPES-NaOH, pH 7.5, 10% (v/v) glycerol, 1 mM
DTT, 1 mM EDTA, one Complete-Mini protease inhibitor
cocktail tablet (Roche) per 7 ml buffer). The lysates were
sonicated on ice three times for 30 s and then clarified by
centrifugation at 4°C in an Eppendorf microfuge. The ly-
sates were dialyzed overnight against low salt buffer (100
mM NaCl, 20 mM HEPES-NaOH, pH 7.5, 10% (v/v) glyc-
erol, 1 mM DTT, 0.1 mM EDTA) and then cleared by
centrifugation at 4°C for 30 min in an Eppendorf microfuge.
After the addition of 1 M MgCl2 to 20 mM and 200 units of
DNase I, the lysates were incubated at 4°C for 2 h and then
stored at 80°C.
UL9-binding assay
Five hundred-milliliter cultures of DH5 E. coli contain-
ing either the pB1 or pD27 plasmid (Arbuckle and Stow,
1993; Boehmer and Lehman, 1993b) were grown in Luria
broth overnight at 37°C. The pelleted cells were washed
three times with 100 ml TE (10 mM Tris-HCl, pH 7.6, 1
mM EDTA). After resuspension in 10 ml lysis buffer (50
mM Tris-Cl, pH 7.6, 150 mM NaCl, 0.05% Tween 20, 1
mM EDTA, one Complete-Mini protease inhibitor cocktail
tablet per 10 ml buffer), lysozyme was added to 200 g/ml,
and the cells were incubated at room temperature for 20
min. The cells were sonicated on ice, and the lysates were
clarified by centrifugation at 4°C in a Sorvall centrifuge at
15,000 rpm for 1 h. The lysates were incubated overnight at
4°C after the addition of 1 M MgCl2 to 20 mM and 400
units of DNase I. The lysates were aliquoted and stored at
80°C.
One milliliter of B1 or D27 lysate was added to 0.5 ml of
IgG Sepharose Fast Flow 6, equilibrated as per manufac-
turer’s directions (Pharmacia Biotech), batchwise in mi-
crofuge tubes. The slurry was incubated at 4°C for 30 min
with gentle agitation. The IgG Sepharose slurry was washed
three times with TST buffer (50 mM Tris-Cl, pH 7.6, 150
mM NaCl, 0.05% Tween 20), and then twice with low salt
buffer (100 mM NaCl, 20 mM HEPES-NaOH, pH 7.5, 10%
(v/v) glycerol, 1 mM DTT, 0.1 mM EDTA). After 0.5 ml of
either wild-type or d105 containing extract was added to the
protein A-UL9/IgG Sepharose preparations, the slurry was
incubated for 1 h at 4°C with gentle agitation. The slurry
was centrifuged at 4°C in an Eppendorf microfuge for 1
min. The supernatant was removed and kept as the unbound
fraction. The slurry was subsequently washed twice with 0.5
ml of low salt buffer and then 0.5 ml of high salt elution
buffer (1 M NaCl, 20 mM HEPES-NaOH, pH 7.5, 10%
(v/v) glycerol, 1 mM DTT, 0.1 mM EDTA). The two 0.5-ml
wash fractions were combined for a final volume of 1 ml. A
portion of each fraction (1/10 total volume) was separated
by SDS-PAGE, transferred to PVDF membrane (BioRad),
and probed with the 3-83 ICP8 polyclonal antibody. On
another gel, decreasing 2-fold dilutions equivalent to 1/10,
1/20, and 1/40 of the input protein extracts were analyzed in
parallel to monitor input and recovery levels.
Western blot analysis of proteins
For the immunodetection of wild-type or mutant ICP8 by
Western blot, the 3–83 polyclonal antibody was used at a
dilution of 1:1000 in TBST (20 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% Tween 20). The anti-GFP polyclonal anti-
body (Clontech) was used at a dilution of 1:1000 in TST.
The membrane was blocked with TBST plus 5% milk for 30
min at room temperature before the addition of the 3–83
antibody. The membrane was washed three times for 15 min
with TBST at room temperature after primary and second-
ary antibody incubations. An HRP-conjugated goat anti-
rabbit secondary antibody (Santa Cruz Biotechnology) was
used at a dilution of 1:5000 in TBST. Enhanced chemilu-
minescent reagents were used as directed by the manufac-
turer (Amersham Pharmacia Biotech).
Plaque reduction assay
Vero cells in 6-well trays were transfected using Lipo-
fectamine. A total of 4 g of DNA consisting of 0.25 g
KOS 1.1 viral DNA, 0.5 g of the indicated wild-type or
mutant ICP8 plasmid, and 3.25 g of plasmid pCI DNA as
carrier DNA was used per transfection reaction. At 24 h
posttransfection, the cells were washed with PBS and over-
layed with DMEM  1% FBS and human sera to allow
plaques to form. The cells were fixed at 4 days posttrans-
fection for plaque enumeration.
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